Advances in targeting cell surface signalling molecules for immune modulation

Sheng Yao, Yuwen Zhu, Lieping Chen

Research output: Contribution to journalArticle

Abstract

The past decade has witnessed a surge in the development of immunomodulatory approaches to combat a broad range of human diseases, including cancer, viral infections, autoimmunity and inflammation as well as in the prevention of transplant rejection. Immunomodulatory approaches mostly involve the use of monoclonal antibodies or recombinant fusion proteins that target cell surface signalling molecules on immune cells to drive immune responses towards the desired direction. Advances in our understanding of the human immune system, along with valuable lessons learned from the first generation of therapeutic biologics, are aiding the design of the next generation of immunomodulatory biologics with better therapeutic efficacy, minimized adverse effects and long-lasting clinical benefit. The recent encouraging results from antibodies targeting programmed cell death protein 1 (PD1) and B7 homolog 1 (B7H1; also known as PDL1) for the treatment of various advanced human cancers show that immunomodulatory therapy has come of age.

Original languageEnglish (US)
Pages (from-to)130-146
Number of pages17
JournalNature Reviews Drug Discovery
Volume12
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Biological Products
Programmed Cell Death 1 Receptor
Recombinant Fusion Proteins
Immunomodulation
Graft Rejection
Virus Diseases
Autoimmunity
Immune System
Neoplasms
Therapeutics
Monoclonal Antibodies
Inflammation
Antibodies
Direction compound

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Advances in targeting cell surface signalling molecules for immune modulation. / Yao, Sheng; Zhu, Yuwen; Chen, Lieping.

In: Nature Reviews Drug Discovery, Vol. 12, No. 2, 02.2013, p. 130-146.

Research output: Contribution to journalArticle

Yao, Sheng ; Zhu, Yuwen ; Chen, Lieping. / Advances in targeting cell surface signalling molecules for immune modulation. In: Nature Reviews Drug Discovery. 2013 ; Vol. 12, No. 2. pp. 130-146.
@article{4c01dc1d971f4e19b3001905e7b26957,
title = "Advances in targeting cell surface signalling molecules for immune modulation",
abstract = "The past decade has witnessed a surge in the development of immunomodulatory approaches to combat a broad range of human diseases, including cancer, viral infections, autoimmunity and inflammation as well as in the prevention of transplant rejection. Immunomodulatory approaches mostly involve the use of monoclonal antibodies or recombinant fusion proteins that target cell surface signalling molecules on immune cells to drive immune responses towards the desired direction. Advances in our understanding of the human immune system, along with valuable lessons learned from the first generation of therapeutic biologics, are aiding the design of the next generation of immunomodulatory biologics with better therapeutic efficacy, minimized adverse effects and long-lasting clinical benefit. The recent encouraging results from antibodies targeting programmed cell death protein 1 (PD1) and B7 homolog 1 (B7H1; also known as PDL1) for the treatment of various advanced human cancers show that immunomodulatory therapy has come of age.",
author = "Sheng Yao and Yuwen Zhu and Lieping Chen",
year = "2013",
month = "2",
doi = "10.1038/nrd3877",
language = "English (US)",
volume = "12",
pages = "130--146",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Advances in targeting cell surface signalling molecules for immune modulation

AU - Yao, Sheng

AU - Zhu, Yuwen

AU - Chen, Lieping

PY - 2013/2

Y1 - 2013/2

N2 - The past decade has witnessed a surge in the development of immunomodulatory approaches to combat a broad range of human diseases, including cancer, viral infections, autoimmunity and inflammation as well as in the prevention of transplant rejection. Immunomodulatory approaches mostly involve the use of monoclonal antibodies or recombinant fusion proteins that target cell surface signalling molecules on immune cells to drive immune responses towards the desired direction. Advances in our understanding of the human immune system, along with valuable lessons learned from the first generation of therapeutic biologics, are aiding the design of the next generation of immunomodulatory biologics with better therapeutic efficacy, minimized adverse effects and long-lasting clinical benefit. The recent encouraging results from antibodies targeting programmed cell death protein 1 (PD1) and B7 homolog 1 (B7H1; also known as PDL1) for the treatment of various advanced human cancers show that immunomodulatory therapy has come of age.

AB - The past decade has witnessed a surge in the development of immunomodulatory approaches to combat a broad range of human diseases, including cancer, viral infections, autoimmunity and inflammation as well as in the prevention of transplant rejection. Immunomodulatory approaches mostly involve the use of monoclonal antibodies or recombinant fusion proteins that target cell surface signalling molecules on immune cells to drive immune responses towards the desired direction. Advances in our understanding of the human immune system, along with valuable lessons learned from the first generation of therapeutic biologics, are aiding the design of the next generation of immunomodulatory biologics with better therapeutic efficacy, minimized adverse effects and long-lasting clinical benefit. The recent encouraging results from antibodies targeting programmed cell death protein 1 (PD1) and B7 homolog 1 (B7H1; also known as PDL1) for the treatment of various advanced human cancers show that immunomodulatory therapy has come of age.

UR - http://www.scopus.com/inward/record.url?scp=84873372202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873372202&partnerID=8YFLogxK

U2 - 10.1038/nrd3877

DO - 10.1038/nrd3877

M3 - Article

C2 - 23370250

AN - SCOPUS:84873372202

VL - 12

SP - 130

EP - 146

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 2

ER -